These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16481305)

  • 1. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
    Zhang WX; Lai V; Mutimer D; Mirza D
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):154-6. PubMed ID: 16481305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
    Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study.
    Limquiaco JL; Wong J; Wong VW; Wong GL; Tse CH; Chan HY; Kwan KY; Lai PB; Chan HL
    J Med Virol; 2009 Feb; 81(2):224-9. PubMed ID: 19107976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
    Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
    Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
    J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
    Perrillo R; Schiff E; Yoshida E; Statler A; Hirsch K; Wright T; Gutfreund K; Lamy P; Murray A
    Hepatology; 2000 Jul; 32(1):129-34. PubMed ID: 10869300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
    Lo CM; Liu CL; Lau GK; Chan SC; Ng IO; Fan ST
    Liver Transpl; 2005 Jul; 11(7):807-813. PubMed ID: 15973721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
    Chen CH; Wang JH; Lee CM; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    Antivir Ther; 2006; 11(6):771-8. PubMed ID: 17310821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
    Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
    Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
    Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
    Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
    J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
    Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.